MedTech Dive2d agobullish
Cordis wins FDA approval for sirolimus-eluting balloonThe approval gives physicians an alternative to uncoated balloons and Boston Scientific’s paclitaxel-coated device.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
146last 24h
877last 7d
147● bullish (7d)
96● bearish (7d)
214publishers
Motley Fool29d agobearish
Stock Market Today, Aug. 26: Boston Scientific Shares Fall 5% on Cybersecurity Incident and Product RecallOn Aug. 26, 2026, a cyberattack halted order processing and shipping at the medical device maker, leaving investors uncertain about the speed of recovery and near-term shipment delays.
Simply Wall St.56d agobearish
Boston Scientific (BSX) Is Up 7.1% After Q2 Beat, Recall And Major Restructuring Plan - Has The Bull Case Changed?Boston Scientific recently reported its second-quarter 2026 results, showing sales of US$5,442 million and net income of US$907 million, alongside issuing a recall of its Rapid Refill Continuous Injection System and initiating a multi-year global restructuring plan aimed at cost efficiencies. While the company raised full-year 2026 net sales growth expectations to approximately 5.5%–6.5%, it also outlined a restructuring program costing up to US$800 million and targeting around US$500...
MedTech Dive77d agobullish
J&J wins FDA approval for dual-energy ablation catheterJohnson & Johnson expects U.S. physicians to perform the first procedures with the device this summer as it starts a phased commercial rollout.